X4 Pharmaceuticals, Inc. (XFOR)

Market Cap	373.23M +498.3%
Revenue (ttm)	35.11M +1,273.2%
Net Income	-79.20M
EPS	-1.87
Shares Out	90.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,252
Open	4.010
Previous Close	4.050
Day's Range	3.920 - 4.150
52-Week Range	1.350 - 9.699
Beta	0.46
Analysts	Strong Buy
Price Target	25.20 (+513.89%)
Earnings Date	Mar 17, 2026

About XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: XFOR
• Website: https://www.x4pharma.com

Financial Performance

In 2025, X4 Pharmaceuticals's revenue was $35.11 million, an increase of 1273.21% compared to the previous year's $2.56 million. Losses were -$79.20 million, 111.5% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price target is $25.2, which is an increase of 513.89% from the latest price.

Price Target

$25.2

(513.89% upside)

Analyst Consensus: Strong Buy